Laboratory Corporation of Ameri – Consensus Indicates Potential 33.2% Upside
Laboratory Corporation of Ameri found using ticker (LH) now have 13 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 320 and 265 with a mean TP of 303.69. Given that the stocks previous close was at 228.01 this would imply there is a potential upside of 33.2%. The 50 day moving average now sits at 245.32 and the 200 day moving average is 263.55. The market cap for the company is $20,364m. Visit the company website at: https:||www.labcorp.com [stock_market_widget type="chart" template="basic" color="green" assets="LH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $27,124m based on the market concensus. Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD).
Laboratory Corporation of Ameri – Consensus Indicates Potential 33.2% Upside
Laboratory Corporation of Ameri found using ticker (LH) now have 13 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 320 and 265 with a mean TP of 303.69. Given that the stocks previous close was at 228.01 this would imply there is a potential upside of 33.2%. The 50 day moving average now sits at 245.32 and the 200 day moving average is 263.55. The market cap for the company is $20,364m. Visit the company website at: https:||www.labcorp.com [stock_market_widget type="chart" template="basic" color="green" assets="LH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $27,124m based on the market concensus. Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD).